Clonatest

Immunoassay for in vitro quantitative determination of total prostate specific antigen (tPSA) in human serum or plasma, and clinically mainly used for the assisted diagnosis and differential diagnosis of prostate diseases.

Immunoassay for in vitro quantitative determination of free prostate specific antigen (fPSA) in human serum or plasma. The ratio of fPSA/tPSA can be used for the differential diagnosis of prostate cancer and benign prostatic hyperplasia. Prostate Specific Antigen (PSA) is a member of human prostate kallikrein gene family, it is a serine protease that contains chymotrypsin-like activity.

Immunoassay for in vitro quantitative determination of free prostate specific antigen (fPSA) in human serum or plasma. The ratio of fPSA/tPSA can be used for the differential diagnosis of prostate cancer and benign prostatic hyperplasia. Prostate Specific Antigen (PSA) is a member of human prostate kallikrein gene family, it is a serine protease that contains chymotrypsin-like activity.

Carbohydrate Antigen 19-9 eCLIA is an immunoassay reagent for in vitro quantitative determination of Carbohydrate Antigen 19-9 (CA19-9) in human serum or plasma by fully automated immunoassay analyzer monitor the therapeutic effect of pancreatic and other digestive tract malignant tumors.

Carbohydrate Antigen 19-9 eCLIA is an immunoassay reagent for in vitro quantitative determination of Carbohydrate Antigen 19-9 (CA19-9) in human serum or plasma by fully automated immunoassay analyzer monitor the therapeutic effect of pancreatic and other digestive tract malignant tumors.

Immunoassay for in vitro quantitative determination of alpha-fetoprotein (AFP) in human serum or plasma samples, and clinically mainly used for the assisted diagnosis, efficacy determination and prognosis observation of primary liver cancer.

Immunoassay for in vitro quantitative determination of alpha-fetoprotein (AFP) in human serum or plasma samples, and clinically mainly used for the assisted diagnosis, efficacy determination and prognosis observation of primary liver cancer.

Cytokeratin Fragment 19 eCLIA is an immunoassay reagent for in vitro quantitative determination of Cytokeratin Fragment 19 (CYFRA21-1) in human serum and plasma by automated immunassay analyzer to aid diagnosis of non-small cell lung cancer.

Cytokeratin Fragment 19 eCLIA is an immunoassay reagent for in vitro quantitative determination of Cytokeratin Fragment 19 (CYFRA21-1) in human serum and plasma by automated immunassay analyzer to aid diagnosis of non-small cell lung cancer.

Immunoassay for the in vitro quantitative determination of N-terminal pro B-type natriuretic peptide in human plasma. Heart failure (HF) is complex clinical symptoms of lesion of myocardial structure and function, caused by myocardial infarction, cardiomyopathy, hypertension, inflammation and so on. The main manifestations are dyspnea, weakness and fluid retention, eventually leading to lowering the ventricular pumping and filling function. N-terminal pro B-type natriuretic peptide (NT-proBNP) and B-type natriuretic peptide (BNP) are recommended indicators of heart failure.

SARS-CoV-2 Neutralization Antibody eCLIA is intended for in vitro quantitative determination of neutralizing antibodies to SARS-CoV-2 in human serum and plasma. The SARS-CoV-2 Neutralization Antibody eCLIA as an aid in indentifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

SARS-CoV-2 Neutralization Antibody eCLIA is intended for in vitro quantitative determination of neutralizing antibodies to SARS-CoV-2 in human serum and plasma. The SARS-CoV-2 Neutralization Antibody eCLIA as an aid in indentifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.